Department of Clinical Research, Rasayani Biologics Pvt. Ltd., Pune, Maharashtra, India.
Department of Oncology (Ayurveda), Rasayu Cancer Clinic, Pune, Maharashtra, India.
J Cancer Res Ther. 2020 Oct-Dec;16(6):1210-1214. doi: 10.4103/jcrt.JCRT_96_20.
Anorexia and cachexia are major clinical problems seen in a large proportion of patients with advanced cancer. Weight loss has also been identified as an indicator of poor prognosis in cancer patients. Around 20% of patients with advanced cancer present mortality from the effects of malnutrition rather than from cancer itself. Early nutrition intervention has seen to improve outcomes in cancer patients such as weight gain, treatment tolerance, and improved quality of life (QoL). Effective therapies for addressing these threatening conditions are lacking. Pharmacotherapeutic agents such as corticosteroids, megestrol acetate, and cyproheptadine have several adverse reactions and also lack satisfactory results. Rasayana therapy is known to prevent loss of body mass and at the same time help to improve appetite and increase patient's QoL. The Rasayana compound used by us to prevent cachexia mainly includes swarna sindoor, Hirak bhasma, and suvarna bhasma. To evaluate benefits of Rasayana therapy on these variables, we maintain complete documentation of different clinical variables in all cancer patients. Here, in this observational study, we analyzed the data collected from a group of stage IV breast cancer patients (n = 30) receiving Rasayana therapy. Patients were followed at an interval of every 15 days from baseline for 3 months. Furthermore, at each visit, there weight was recorded on calibrated digital weight balance. QoL in these patients was recorded at quarterly interval using functional assessment of cancer therapies questionnaire. It was seen that in the duration of 3 months patients appetite increased significantly (P = 0.03). Significant weight gain was seen in patients (P = 0.04). Significant improvement was also seen in QoL especially related to QoL subdomains of physical wellbeing (P = 0.01), emotional wellbeing (P < 0.04), and functional wellbeing (P < 0.001). Rasayana therapy was seen to be well tolerated by all patients.
厌食症和恶病质是大量晚期癌症患者中主要的临床问题。体重减轻也被确定为癌症患者预后不良的指标。大约 20%的晚期癌症患者因营养不良而非癌症本身而死亡。早期营养干预已被证明可改善癌症患者的结局，如体重增加、治疗耐受性和提高生活质量（QoL）。目前缺乏针对这些威胁性疾病的有效治疗方法。皮质类固醇、甲地孕酮和赛庚啶等药物治疗剂有多种不良反应，结果也不尽如人意。瑞萨扬疗法被认为可以防止体重减轻，同时有助于改善食欲并提高患者的 QoL。我们用于预防恶病质的瑞萨扬化合物主要包括 swarna sindoor、Hirak bhasma 和 suvarna bhasma。为了评估瑞萨扬疗法对这些变量的益处，我们在所有癌症患者中都完整记录了不同的临床变量。在这里，在这项观察性研究中，我们分析了接受瑞萨扬疗法的一组 IV 期乳腺癌患者（n = 30）的数据。患者从基线开始每 15 天随访一次，持续 3 个月。此外，每次就诊时，都会在经过校准的数字体重秤上记录患者的体重。这些患者的 QoL 每季度使用癌症治疗功能评估问卷记录一次。结果显示，在 3 个月的时间内，患者的食欲显著增加（P = 0.03）。患者的体重明显增加（P = 0.04）。QoL 也有显著改善，特别是与身体幸福感（P = 0.01）、情绪幸福感（P < 0.04）和功能幸福感（P < 0.001）相关的 QoL 亚领域。所有患者均能耐受瑞萨扬疗法。
